Regional Variation in Hemoglobin Distribution Among Individuals With CKD: the ISN International Network of CKD Cohorts


1Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ontario, Canada; 2Methodology and Analytics, BC Renal, Vancouver, British Columbia, Canada; 3Division of Nephrology, Department of Pediatrics, University of British Columbia, Canada; 4CEESP, University Paris-Saclay, UVSQ, Inserm, Clinical Epidemiology Team, Villejuif, France; 5School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada; 6Department of Pediatrics, Seoul National University College of Medicine, Seoul, South Korea; 7Institute of Medical Biometry, University Hospital Heidelberg, Germany; 8Research Department, Pro-rim Foundation, Joinville-SC, Brazil; 9School of Medicine, UNIVILLE, Joinville-SC, Brazil; 10Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, the Netherlands; 11ERA Registry, Amsterdam UMC Location University of Amsterdam, Medical Informatics, Amsterdam, Netherlands; 12Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; 13Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; 14Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; 15Institute of Public Health, Charité Universitätsmedizin Berlin, Germany; 16Department of Internal Medicine IV (Nephrology and Hypertension), Medical University of Innsbruck, Innsbruck, Austria; 17Institute of Applied Health Sciences, University of Birmingham, Birmingham, UK; 18Division of Nephrology, Endocrinology, and Metabolism, Tokai University School of Medicine, Isehara, Japan; 19Division of Nephrology, Children’s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; 20University of Mississippi Medical Center, Jackson, Mississippi, USA; 21Department of Anatomy and Cell Biology, Monash University, Clayton, Victoria, Australia; 22Centre for Chronic Disease, University of Queensland, Brisbane, Queensland, Australia; 23Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; 24George Institute for Global Health, UNSW, New Delhi, India; 25School of Public Health, Imperial College, London, UK; 26Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India; 27Departments of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 28Department of Internal Medicine, Seoul National University, Seoul, South Korea; 29Department of Medicine, University of Nigeria Teaching Hospital, Enugu, Nigeria; 30DOPPS Program Area, Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA; 31School of Medicine, Pontifícia Universidade Católica do Parana, Curitiba, Brazil; 32Nephrological Center, Villingen-Schwenningen, Germany; 33Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK; 34Pediatric Nephrology Division, University Children’s Hospital, Heidelberg, Germany; 35Department of Nephrology, Charité University Medicine, Berlin, Germany; 36Hemodialysis Unit, CASMU-IAMP, Montevideo, Uruguay; 37Renal Unit, Department of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla, Enugu, Nigeria; 38Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; 39Peking University Institute of Nephrology, Peking University Health Science Center, Beijing, China; 40Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India; 41Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia; and 42Centre for Kidney Research and Innovation, Academic Unit for Translational Medical Sciences, University of Nottingham School of Medicine, Nottingham, UK

Correspondence: Mark Canney, 1967 Riverside Drive, Ottawa Ontario K1H 7W9, Canada. E-mail: mcanney@toh.ca

Received 11 July 2023; accepted 31 July 2023; published online 12 August 2023

2056 Kidney International Reports (2023) 8, 2056–2067
**Introduction:** Despite recognized geographic and sex-based differences in hemoglobin in the general population, these factors are typically ignored in patients with chronic kidney disease (CKD) in whom a single therapeutic range for hemoglobin is recommended. We sought to compare the distribution of hemoglobin across international nondialysis CKD populations and evaluate predictors of hemoglobin.

**Methods:** In this cross-sectional study, hemoglobin distribution was evaluated in each cohort overall and stratified by sex and estimated glomerular filtration rate (eGFR). Relationships between candidate predictors and hemoglobin were assessed from linear regression models in each cohort. Estimates were subsequently pooled in a random effects model.

**Results:** A total of 58,613 participants from 21 adult cohorts (median eGFR range of 17–49 ml/min) and 3 pediatric cohorts (median eGFR range of 26–45 ml/min) were included with broad geographic representation. Hemoglobin values varied substantially among the cohorts, overall and within eGFR categories, with particularly low mean hemoglobin observed in women from Asian and African cohorts. Across the eGFR range, women had a lower hemoglobin compared to men, even at an eGFR of 15 ml/min (mean difference 5.3 g/l, 95% confidence interval [CI] 3.7–6.9). Lower eGFR, female sex, older age, lower body mass index, and diabetic kidney disease were all independent predictors of a lower hemoglobin value; however, this only explained a minority of variance (R² 7%–44% across cohorts).

**Conclusion:** There are substantial regional differences in hemoglobin distribution among individuals with CKD, and the majority of variance is unexplained by demographics, eGFR, or comorbidities. These findings call for a renewed interest in improving our understanding of hemoglobin determinants in specific CKD populations.


KEYWORDS: anemia; chronic kidney disease; geography; glomerular filtration rate; hemoglobin; sex

© 2023 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
with defined objectives and prospective data collection. The present analysis included study participants who had an eGFR below 60 ml/min per 1.73 m² and complete data for a core set of variables including age, sex, and hemoglobin. Kidney transplant recipients and participants receiving dialysis at the time of hemoglobin measurement were excluded. The pediatric cohorts 4C (Europe), CKiD (US), and KNOW-Ped CKD (Korea) contributed to the descriptive phase of the analysis. The distributed network approach is similar to a 2-stage individual participant data meta-analysis; however, it uses standardized data collection and methods across cohorts, as opposed to using published data from previous studies. Participating investigators had the following options: (i) providing deidentified individual-level data to a central hub at the University of British Columbia, Canada, for analysis or (ii) conducting the analysis and transferring the output to the central hub for pooled analysis (Supplementary Figure S1). For both options, a study protocol was sent to investigators. Ethical approval for the study was granted from the research ethics board at each participating site.

Variable Definitions
A variable dictionary was created to harmonize data extraction, coding, and labeling of variables (Supplementary Table S2). The first available hemoglobin value (in grams per liter, g/l) was used for each participant. Glomerular filtration rate was estimated by using the 2009 Chronic Kidney Disease Epidemiology Collaboration formula and using serum creatinine standardized to isotope dilution mass spectrometry. The bedside Schwartz equation was used to estimate glomerular filtration rate in pediatric cohorts. Albinuminuria was measured by the albumin-to-creatinine ratio (ACR, in mg/g) and classified as per Kidney Disease Improving Global Outcomes stages as A1 (ACR <30 mg/g), A2 (ACR 30–299 mg/g), or A3 (ACR ≥ 300 mg/g). The closest value of eGFR or ACR within 3 months of the date of the index hemoglobin measurement was chosen. Iron saturation was measured in 9 adult cohorts. Etiology of kidney disease was classified as diabetic kidney disease, hypertension, glomerulonephritis, polycystic kidney disease, or ‘other’ based on a physician diagnosis or a kidney biopsy. A small number of cohorts did not collect data for specific etiologies such as polycystic kidney disease (Supplementary Table S2). In some instances, the ‘other’ category contained unknown or missing cases. Definitions for atherosomatous cardiovascular disease, heart failure, and diabetes mellitus are provided in Supplementary Table S2. Body mass index (BMI) was calculated as weight (kg) divided by square height (m²) and categorized as <18.5, 18.5 to 24.9, 25.0 to 29.9, or ≥30.0. Smoking status was classified as current, former, or never. Use of erythropoiesis stimulating agent (ESA) therapy and renin-angiotensin-aldosterone-system (RAAS) inhibitors was ascertained as a yes/no exposure using medication records and/or Anatomical Therapeutic Chemical codes. Altitude was categorized as 1 to 499, 500 to 1000 and >1000 meters above sea level based on the location of residency or, if unavailable, the location of the center of study enrollment.

Statistical Analysis
To compare the distribution of hemoglobin across the cohorts, we report summary statistics (mean and SD) stratified by sex and eGFR category (<20, 20–29, 30–44, and 45–59 ml/min per 1.73 m²). In each of the adult cohorts, the association between hemoglobin and candidate predictor variables was examined in a series of linear regression models. To maximize cohort participation, the first set of models included a core set of variables that was available in all cohorts, including age (per 10-year increase), sex, year of hemoglobin measurement, and eGFR (per 10 ml/min per 1.73 m² increase). An extended multivariable model incorporated comorbidities (cardiovascular disease, diabetes, and heart failure), BMI, albuminuria categories, and etiology of CKD. Due to interdependence between diabetes mellitus and etiology of CKD, estimates for etiology of CKD are presented separately for individuals with and without diabetes mellitus. Potential interactions were identified a priori between eGFR and the following variables: sex, age, and etiology of CKD. In an exploratory analysis, smoking status, use of RAAS inhibitors and altitude were added separately to the extended model. Only cohorts that collected data for each variable in a multivariable model could be included in that model. For categorical variables with missing values, a separate category was created to ensure that sequential models included the same individuals from each cohort, thus facilitating a better comparison between models. A complete case analysis was conducted as a sensitivity analysis. Covariate coefficient estimates from each cohort were subsequently pooled in a random effects meta-analysis. Heterogeneity in beta-coefficients was assessed using tau (the between-cohort SD) and the I² statistic. To remove potential confounding from variable use of (or access to) ESA therapy in different countries, we repeated the analysis in patients unexposed to ESA treatment. All analyses were performed with SAS version 9.4 (SAS Institute Inc., Cary, NC) and R version 4.2.0 (R Core Team 2014, Vienna, Austria).
RESULTS

Participant Characteristics

A total of 58,613 participants from 24 cohorts were included. Characteristics of included participants by cohort are summarized in Table 1. Three cohorts were pediatric cohorts including 1107 participants with median age ranging from 10 to 14 years. In the remaining 21 adult cohorts, median age ranged from 47 years in H3AKDN Enugu Site (Africa) to 84 years in CKDBIS (Germany). The majority of participants were male except for CKD-BIS and the primary care cohorts RRID (UK) and PROVALID (Europe), which had a slight majority of women. The proportion of participants with diabetes mellitus ranged from 7.5% in PSI BIND-NL (Netherlands) to 58% in CKDopps (US). One cohort (PROVALID) specifically recruited individuals in a primary care setting with diabetes. Kidney-specific characteristics are summarized in Table 2. Participants from pediatric cohorts had moderate to advanced CKD with median eGFR values of 26 (4C), 32 (KNOW-Ped CKD), and 45 ml/min per 1.73 m² (CKiD). The median eGFR in adult CKD cohorts ranged between 17 ml/min per 1.73 m² in EQUAL (Europe) and 49 ml/min per 1.73 m² in RRID. The proportion of participants with severe albuminuria varied between 2.7% in NRHP (Uruguay) and 68% in CKDQLD (Australia). In general, albuminuria values were known for the majority of participants; however, missingness was higher in cohorts that recruited individuals with more advanced CKD (eGFR < 30 ml/min per 1.73 m²). The etiology of CKD was unknown for a substantial number of participants in most cohorts. Where the cause was known (physician-diagnosed or biopsy-proven), the most common causes were hypertension and diabetic kidney disease, except for C-STRIDE (China), CKD-JAC (Japan), and H3AKDN Enugu Site, which had a relatively higher prevalence of glomerulonephritis. A total of 4947 participants (8.4%) were receiving ESA therapy (Table 1).

Hemoglobin Distribution Among Cohorts

The distribution of hemoglobin across all participating cohorts is provided in Supplementary Table S3 and summarized graphically in Figure 1. Among pediatric cohorts, mean (SD) hemoglobin ranged from 113 (19) g/l to 119 (15) g/l in female participants, and from 118 (16) g/l to 122 (18) g/l in male participants. In adult cohorts, there was considerable variation in hemoglobin values in both men and women. For example, in women, the mean (SD) hemoglobin ranged from 94 (21) g/l to 130 (12) g/l. Even within the same world region, there was substantial variation in hemoglobin distribution. Among men participating in European cohorts, the mean (SD) hemoglobin varied between 117 (16) g/l and

Table 1. Participant characteristics by cohort

<table>
<thead>
<tr>
<th>Cohort</th>
<th>N</th>
<th>Age (Median, IQR)</th>
<th>Female (%)</th>
<th>&lt;18.5</th>
<th>18.5–24.9</th>
<th>25–29.9</th>
<th>≥30</th>
<th>Unknown</th>
<th>DM (%)</th>
<th>CVD (%)</th>
<th>CHF (%)</th>
<th>ESA (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORE-CKD</td>
<td>1312</td>
<td>64 (57, 69)</td>
<td>34.5</td>
<td>2.3</td>
<td>43.4</td>
<td>37.3</td>
<td>15.7</td>
<td>1.3</td>
<td>50.8</td>
<td>16.5</td>
<td>1.0</td>
<td>2.5</td>
</tr>
<tr>
<td>C-STRIDE</td>
<td>2302</td>
<td>54 (43, 63)</td>
<td>42.7</td>
<td>2.5</td>
<td>41.2</td>
<td>26.3</td>
<td>5.0</td>
<td>25.1</td>
<td>23.8</td>
<td>10.4</td>
<td>1.2</td>
<td>15.0</td>
</tr>
<tr>
<td>IOKD</td>
<td>3506</td>
<td>53 (44, 60)</td>
<td>33.6</td>
<td>6.9</td>
<td>47.4</td>
<td>30.8</td>
<td>12.1</td>
<td>2.7</td>
<td>38.0</td>
<td>22.6</td>
<td>11.9</td>
<td>2.9</td>
</tr>
<tr>
<td>KNOW-CKD</td>
<td>1430</td>
<td>58 (50, 66)</td>
<td>37.9</td>
<td>2.5</td>
<td>54.9</td>
<td>35.2</td>
<td>6.6</td>
<td>0.8</td>
<td>42.2</td>
<td>16.8</td>
<td>2.2</td>
<td>11.7</td>
</tr>
<tr>
<td>CKD-JAC</td>
<td>2494</td>
<td>63 (56, 70)</td>
<td>36.3</td>
<td>6.9</td>
<td>55.5</td>
<td>22.3</td>
<td>5.0</td>
<td>10.3</td>
<td>38.4</td>
<td>22.8</td>
<td>4.8</td>
<td>13.8</td>
</tr>
<tr>
<td>CKD-QLD</td>
<td>1883</td>
<td>71 (61, 78)</td>
<td>45.6</td>
<td>1.2</td>
<td>17.7</td>
<td>28.5</td>
<td>44.9</td>
<td>7.8</td>
<td>47.6</td>
<td>19.6</td>
<td>8.2</td>
<td>4.5</td>
</tr>
<tr>
<td>CanPREDDICT</td>
<td>2526</td>
<td>70 (61, 77)</td>
<td>37.5</td>
<td>0.5</td>
<td>5.7</td>
<td>8.2</td>
<td>9.7</td>
<td>76.0</td>
<td>48.1</td>
<td>45.2</td>
<td>26.9</td>
<td>20.3</td>
</tr>
<tr>
<td>IRC</td>
<td>4224</td>
<td>62 (56, 68)</td>
<td>44.1</td>
<td>0.5</td>
<td>13.4</td>
<td>28.8</td>
<td>56.8</td>
<td>9.5</td>
<td>53.4</td>
<td>33.1</td>
<td>10.5</td>
<td>3.6</td>
</tr>
<tr>
<td>CKDopps US</td>
<td>2119</td>
<td>70 (61, 77)</td>
<td>48.6</td>
<td>1.1</td>
<td>13.1</td>
<td>23.7</td>
<td>50.0</td>
<td>12.1</td>
<td>58.0</td>
<td>30.5</td>
<td>16.9</td>
<td>5.2</td>
</tr>
<tr>
<td>CKDopps BR</td>
<td>720</td>
<td>66 (57, 76)</td>
<td>47.2</td>
<td>0.7</td>
<td>20.3</td>
<td>21.1</td>
<td>21.0</td>
<td>37.8</td>
<td>50.7</td>
<td>23.1</td>
<td>16.1</td>
<td>12.2</td>
</tr>
<tr>
<td>NRHP</td>
<td>19,288</td>
<td>73 (65, 79)</td>
<td>42.1</td>
<td>0.6</td>
<td>16.8</td>
<td>28.7</td>
<td>29.3</td>
<td>24.5</td>
<td>37.1</td>
<td>28.2</td>
<td>9.4</td>
<td>7.6</td>
</tr>
<tr>
<td>H3Africa</td>
<td>338</td>
<td>47 (36, 59)</td>
<td>47.9</td>
<td>1.2</td>
<td>8.3</td>
<td>8.6</td>
<td>1.2</td>
<td>80.8</td>
<td>19.5</td>
<td>2.4</td>
<td>0.9</td>
<td>2.7</td>
</tr>
<tr>
<td>CKD-REIN</td>
<td>2946</td>
<td>69 (61, 77)</td>
<td>34.6</td>
<td>4.1</td>
<td>16.1</td>
<td>35.5</td>
<td>34.7</td>
<td>2.1</td>
<td>43.0</td>
<td>36.3</td>
<td>13.2</td>
<td>7.8</td>
</tr>
<tr>
<td>RISIC</td>
<td>790</td>
<td>65 (53, 76)</td>
<td>36.6</td>
<td>0.9</td>
<td>22.7</td>
<td>31.4</td>
<td>40.6</td>
<td>4.4</td>
<td>40.3</td>
<td>35.3</td>
<td>0.0</td>
<td>6.6</td>
</tr>
<tr>
<td>BIS</td>
<td>777</td>
<td>84 (79, 88)</td>
<td>52.3</td>
<td>0.4</td>
<td>25.4</td>
<td>45.6</td>
<td>28.7</td>
<td>0.0</td>
<td>31.0</td>
<td>55.3</td>
<td>46.5</td>
<td>0.5</td>
</tr>
<tr>
<td>EQUAL</td>
<td>1720</td>
<td>76 (71, 81)</td>
<td>34.5</td>
<td>1.2</td>
<td>24.3</td>
<td>34.5</td>
<td>30.8</td>
<td>9.2</td>
<td>41.3</td>
<td>26.3</td>
<td>17.4</td>
<td>24.9</td>
</tr>
<tr>
<td>GCkD</td>
<td>3995</td>
<td>65 (57, 70)</td>
<td>38.1</td>
<td>0.5</td>
<td>18.0</td>
<td>37.2</td>
<td>43.3</td>
<td>1.0</td>
<td>38.2</td>
<td>33.6</td>
<td>19.1</td>
<td>3.0</td>
</tr>
<tr>
<td>CKDopps GERMANY</td>
<td>2638</td>
<td>75 (67, 80)</td>
<td>43.2</td>
<td>1.1</td>
<td>23.4</td>
<td>35.5</td>
<td>37.6</td>
<td>2.5</td>
<td>47.9</td>
<td>29.0</td>
<td>13.4</td>
<td>11.6</td>
</tr>
<tr>
<td>PSI BIND-NL</td>
<td>644</td>
<td>63 (54, 72)</td>
<td>32.3</td>
<td>0.9</td>
<td>29.5</td>
<td>35.4</td>
<td>23.3</td>
<td>10.9</td>
<td>7.5</td>
<td>71.7</td>
<td>6.5</td>
<td>16.9</td>
</tr>
<tr>
<td>RRID</td>
<td>1184</td>
<td>76 (70, 81)</td>
<td>53.7</td>
<td>0.3</td>
<td>19.3</td>
<td>42.4</td>
<td>38.0</td>
<td>0.0</td>
<td>20.3</td>
<td>19.4</td>
<td>4.5</td>
<td>0.0</td>
</tr>
<tr>
<td>PROVALID</td>
<td>870</td>
<td>68 (62, 74)</td>
<td>58.6</td>
<td>0.0</td>
<td>12.8</td>
<td>32.4</td>
<td>53.6</td>
<td>1.2</td>
<td>100.0</td>
<td>42.7</td>
<td>5.8</td>
<td>7.3</td>
</tr>
<tr>
<td>4C</td>
<td>651</td>
<td>12 (9, 14)</td>
<td>33.8</td>
<td>8.1</td>
<td>69.6</td>
<td>11.7</td>
<td>10.6</td>
<td>0.0</td>
<td>0.6</td>
<td>-</td>
<td>-</td>
<td>23.5</td>
</tr>
<tr>
<td>CKD</td>
<td>210</td>
<td>14 (11, 16)</td>
<td>43.3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100.0</td>
<td>0.0</td>
<td>0.5</td>
<td>1.4</td>
<td>22.9</td>
</tr>
<tr>
<td>KNOW-Ped CKD</td>
<td>246</td>
<td>10 (6, 14)</td>
<td>30.9</td>
<td>67.1</td>
<td>29.7</td>
<td>2.4</td>
<td>0.8</td>
<td>0.8</td>
<td>-</td>
<td>0.4</td>
<td>18.3</td>
<td></td>
</tr>
</tbody>
</table>

BMI, body mass index; CHF, congestive heart failure; CVD, cardiovascular disease; DM, diabetes mellitus; ESA, erythropoiesis stimulating agent; IQR, interquartile range.
139 (18) g/l. When comparing world regions, women from Asian cohorts tended to have a lower average hemoglobin than women from European cohorts, and this finding was broadly consistent within categories of eGFR (Supplementary Figure S2). With the exception of H3AKDN Enugu Site, men had a higher hemoglobin value, on average, compared to women from the same cohort. Nine adult cohorts collected data on iron saturation with values available for between 12.6% and 97.8% of participants (Supplementary Table S4). In men, each 10 ml/min per 1.73 m² decrease in eGFR was associated with a 5.8 (95% CI 5.2–6.4) g/l decrease in mean hemoglobin. The corresponding estimate in women was 4.0 (95% CI 3.5–4.5) g/l. There was minimal change in these estimates after multivariable adjustment (Supplementary Table S7). Compared to diabetic kidney disease, glomerulonephritis (pooled mean difference 4.8 (95% CI 2.1–7.6) g/l), polycystic kidney disease (pooled mean difference 6.2 (95% CI 3.9–8.5) g/l) and hypertension (pooled mean difference 6.6 (95% CI 4.7–8.4) g/l) were all associated with higher mean hemoglobin values (Figure 3, Supplementary Table S8A). In a multivariable model, the pattern of differences in hemoglobin by eGFR and cause of CKD was consistent across cohorts with an overall P-value of <0.001 (Supplementary Table S5). For example, in women compared to men, mean hemoglobin was 13.5 (95% CI 11.4–15.7) g/l lower at an eGFR of 60 ml/min per 1.73 m², 10.8 (95% CI 8.9–12.6) g/l lower at an eGFR of 45 ml/min per 1.73 m², 7.9 (95% CI 6.3–9.7) g/l lower at an eGFR of 30 ml/min per 1.73 m², and 5.3 (95% CI 3.7–6.9) g/l lower at an eGFR of 15 ml/min per 1.73 m² (Figure 2, Supplementary Tables S6A–D). There was no attenuation in these estimates after multivariable adjustment.

### Sex Differences in Hemoglobin

To further illustrate differences in mean hemoglobin in men and women across the eGFR spectrum, data from all cohorts were pooled in a violin plot (Figure 2, left panel). In keeping with the bubble plots in Figure 1, mean hemoglobin values varied widely across the cohorts in both sexes and within strata of eGFR. The shape of the hemoglobin distribution was also different by sex, demonstrating a broader dispersion of values in women compared to men. Across all eGFR categories, women tended to have a lower hemoglobin value compared to men; however, the magnitude of these differences was smaller in more advanced CKD compared to earlier stages of CKD (Figure 2, right panel). Evidence of an interaction between sex and eGFR was consistent across cohorts with an overall P-value of <0.001 (Supplementary Table S5). For example, in women compared to men, mean hemoglobin was 13.5 (95% CI 11.4–15.7) g/l lower at an eGFR of 60 ml/min per 1.73 m², 10.8 (95% CI 8.9–12.6) g/l lower at an eGFR of 45 ml/min per 1.73 m², 7.9 (95% CI 6.3–9.7) g/l lower at an eGFR of 30 ml/min per 1.73 m², and 5.3 (95% CI 3.7–6.9) g/l lower at an eGFR of 15 ml/min per 1.73 m² (Figure 2, Supplementary Tables S6A–D). There was no attenuation in these estimates after multivariable adjustment.
these findings was consistent among individuals without diabetes mellitus, whereas there was some attenuation in disease-specific estimates among those with diabetes mellitus (Figure 3, Supplementary Tables S8B and C). There was no statistically significant interaction between eGFR and etiology of CKD based on the pooled analysis.

Other Covariate Associations With Hemoglobin

Cohort-specific and pooled estimates for the independent association between candidate predictor variables and hemoglobin from a multivariable linear regression model are provided in Supplementary Table S9. This analysis included 15 cohorts who had data available for all covariates in the extended model. Overall, each 10-year increase in age was associated with a modest reduction in mean hemoglobin of 0.6 (95% CI 0.27–0.99) g/l. The presence of diabetes mellitus was associated with a 2.5 (95% CI 1.5–3.5) g/l reduction in mean hemoglobin. Compared to individuals with a BMI of 18.5 to 24.9 kg/m², those with a BMI ≥30 kg/m² had, on average, a 5.2 (95% CI 3.9–6.6) g/l higher hemoglobin level. Heart failure was associated with a small reduction in hemoglobin (1.4 g/l, 95% CI 0.7–2.1). No statistically significant associations were found between hemoglobin level and coronary artery disease or categories of albuminuria. The proportion of variance ($R^2$) in hemoglobin explained by this set of covariates, applied in the same way in all cohorts, ranged between 6.9% and 44.3%, representing a modest improvement in $R^2$ compared to the simpler core model (Supplementary Table S10).

In an exploratory analysis, we evaluated the relationship between hemoglobin and smoking status (available in 11 cohorts), use of RAAS inhibitors (available in 13 cohorts) and altitude (available in 8 cohorts). These variables were added separately to the
Previously described extended model. Compared to nonsmokers, current smoking was associated with higher mean hemoglobin (2.1 g/l, 95% CI 1.1–3.1, Supplementary Table S11). Mean hemoglobin was also higher among those living at altitudes higher than 1000 meters compared to those living at sea level (5.4 g/l, 95% CI 0.5–10.4, Supplementary Table S12). The use of RAAS inhibitors was not consistently associated with a difference in hemoglobin (0.07 g/l, 95% CI 1.1 to 1.2, Supplementary Table S13).

**Expected Values of Hemoglobin Based on Specific Patient Characteristics**

To illustrate the possible range in hemoglobin values among patients with CKD, even at the same level of eGFR, we used the extended regression model to generate estimates of hemoglobin conditional on specific patient characteristics (Figure 4). For all comparisons, eGFR was fixed at 34 ml/min per 1.73 m² (overall mean in the study population), and other covariates were held at their mean values unless otherwise specified. The “typical” patient (based on mean values of covariates) across all cohorts was aged 65 years and had an expected hemoglobin value of 124.7 g/l (95% CI 122.2–127.3). A 40-year-old man with glomerulonephritis, a BMI of 30 kg/m² and without diabetes, had an expected hemoglobin value of 133.6 g/l (95% CI 131.4–135.9), whereas a 70-year-old woman with diabetic kidney disease and a BMI of 24 kg/m² had an expected hemoglobin value of 111.6 g/l (95% CI 107.3–116). Between-cohort heterogeneity accounted for a large proportion of variability in these estimates. For example, the pooled estimate for the last patient example had a tau of 7.6 g/l and I² of 96.8%.

**Sensitivity Analysis**

We repeated the analysis among participants unexposed to ESA therapy at the time of hemoglobin measurement. Estimates for mean differences in hemoglobin according to sex (Supplementary Table S14), etiology of CKD (Supplementary Table S15) and other covariates included in the extended multivariable model (Supplementary Table S16) were similar to those of the primary analysis. A complete case analysis (conducted in 10 cohorts who provided individual-level data) produced similar estimates to those of the primary analysis (Supplementary Table S17).

**DISCUSSION**

In this study of over 58,000 individuals with CKD from 24 cohorts representing all major world regions, we observed wide variation in hemoglobin distribution internationally, both overall and within categories of eGFR. Women had a lower hemoglobin value, on average, compared to men in virtually all cohorts, and this difference was evident across the full range of eGFR. In multivariable regression models, we identified independent associations between hemoglobin and sex, eGFR, etiology of CKD, age, BMI, and the presence of heart failure and diabetes. Collectively, however, these variables explained only a minority of variance in hemoglobin.
To our knowledge, this is the first study to describe international differences in hemoglobin concentration in individuals with CKD and across the range of kidney function. The positive association between eGFR and hemoglobin has long been recognized. The largest and most contemporaneous study to demonstrate this association came from the CKD Prognosis Consortium (CKD-PC) and included 254,666 participants from 17 CKD cohorts. Across an eGFR range of 15 to 60 ml/min per 1.73 m², the relationship between eGFR and hemoglobin was linear with a similar reduction in hemoglobin per unit decrease in eGFR that was observed in the present analysis. Similar to the CKD Prognosis Consortium study, we found minimal association of hemoglobin with participant age or the magnitude of albuminuria, and lower hemoglobin values among participants with diabetes compared to those without diabetes. Our study expands on the CKD Prognosis Consortium analysis by including a geographically more diverse population with CKD, with greater representation of people from African and Asian countries. We have also shown the potential contribution of the etiology of CKD to the level of hemoglobin, with higher values observed in individuals with hypertension, glomerulonephritis, and polycystic kidney disease compared to those with diabetic kidney disease. In their framework for diagnosing and classifying CKD, Kidney Disease Improving Global Outcomes recognizes the importance of ascertaining the etiology of CKD; however, this is generally not considered in the assessment of different functions of the kidney. Taking these variables together, a younger male patient with glomerulonephritis and a BMI of 30 kg/m² would be expected to have a hemoglobin of 134 g/l, whereas an older female patient with diabetic kidney disease and a BMI of 24 kg/m² would be expected to have a hemoglobin of 112 g/l at the same eGFR value of 34 ml/min per 1.73 m². This clinical example serves to demonstrate the anticipated variability in hemoglobin distribution based on patient-level characteristics outside of eGFR alone.

Average hemoglobin values were particularly low among women in Asian and African cohorts compared to their European counterparts. This finding mirrors the patterns observed in global studies of anemia prevalence. This regional variation in hemoglobin distribution has not been well described in CKD; and this raises important questions about our understanding of the pathophysiology of anemia in CKD. In the general population, the proportion of prevalent anemia cases attributable to CKD varies significantly by world region, with a much higher attributable fraction observed in high-income Asia Pacific countries compared to South Asian or African countries. It was striking that all cohorts had a high proportion of unexplained variance in hemoglobin. Apart from the predictors of hemoglobin evaluated in the present study, there are other contributors to hemoglobin concentration that would be expected to vary by world region independently of CKD status. Anemia in African countries has been linked to a high prevalence of infections such as malaria, soil-transmitted helminthiasis, and schistosomiasis; whereas, genetic traits such as thalassemia and sickle cell disorders play an important role in the development of anemia in Africa and parts of central and South Asia. The same factors that contribute to variability in hemoglobin distribution internationally could potentially also influence response to anemia therapies, as has been postulated with the use of ESAs. This study represents an important first step in refining our understanding of regional determinants of hemoglobin in individuals with CKD, which has been identified as a key research priority by the International Society of Nephrology as part of its Closing the Gaps initiative.
Across virtually all CKD cohorts, women had a lower hemoglobin compared to men. The magnitude of this difference became smaller with declining levels of eGFR, a finding which has also been observed in studies using measured glomerular filtration rate. This finding nonetheless showed that women continued to have a lower average hemoglobin down to an eGFR of 15 ml/min per 1.73 m². This finding argues against the notion that physiological differences in hemoglobin concentration in men and women should be ignored in the presence of CKD, or that the same target range of hemoglobin should be sought regardless of sex. Previous studies have shown that women receiving dialysis require a higher dose of ESA to achieve the same target hemoglobin as men. Sex differences have been observed for other biomarkers with important implications for health, such as the threshold used for high sensitivity troponin in the diagnosis of myocardial infarction. Our understanding of sex differences in the epidemiology of kidney disease has advanced in recent years; however, many of the discrepancies observed between men and women in CKD outcomes remain unexplained.

The sex-based differences in hemoglobin observed in this study call for research efforts to improve our understanding of the natural history and determinants of hemoglobin trajectory in women with CKD, and call for a renewed interest in broadening our understanding of hemoglobin determinants in specific CKD populations.

**APPENDIX**

**List of Collaborating ISN iNET-CKD Investigators**


**DISCLOSURE**

Authors have received financial support from Agency Nationale de la Recherche, Akademie Niere, Akebia, Alexion, American Society of Nephrology, Amgen, Astellas, Astra Zeneca, AstraZeneca, Baxter, Baxter Healthcare, Bayer, Bayer AG, Biocon, Boehringer Ingelheim, Boehringer-Lilly, Cadilla, Cara Therapeutics, ChongKumDang, CSL Vifor Pharma, Fresenius Medical Care, GSK, Handok, Health system Research Institute, Thailand, International Society of Nephrology, Janssen, Kyowa Kirin Co Ltd, Lilly France, Merck, Merck Sharp & Dohme-Chibret, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, NephroPlus, Novo Nordisk, Otsuka Pharmaceutical,
Pharmacosmos, Reata, Research of Korea Centers for Disease Control and Prevention of Republic of Korea, Roche, Sanofi Genzyme, University of British Columbia, Vertex and Vifor France. Authors have participated in data safety monitoring or advisory boards for Australian Kidney Clinical Trials Network, Bayer, Chinook, CSL Behring, Genentech, GSK, International Society of Nephrology Advocacy Group, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Otsuka Pharmaceuticals and Vertex. Authors have participated in leadership and fiduciary roles for American Journal of Kidney Diseases, BC Renal, Chronic Kidney Disease-Mineral Gone Disease Working Group for European Renal Association, European Kidney Function Consortium, German Society of Nephrology, Kidney Improving Global Outcomes Working Group, Nephrology Dialysis Transplantation and University of British Columbia.

MC is supported by a KRESCENT New Investigator Award. Anna Richards is an employee of, and holds stocks and shares in GSK. All other authors declare no competing interests.

**ACKNOWLEDGMENTS**

The authors thank all participants of the iNET-CKD cohort studies without whom this work would not be possible. This work was supported by an unrestricted grant from GSK, in-kind administrative support from the ISN, and in-kind analytical support from BC Renal.

**SUPPLEMENTARY MATERIAL**

Supplementary File (PDF)

**Figure S1.** Summary of data collection from participating iNET-CKD cohorts for pooled analysis.

**Figure S2.** Mean (SD) hemoglobin values in women (red circles) and men (blue circles) within categories of eGFR for each cohort and grouped by continent.

**Table S1.** Description of iNET-CKD cohorts.

**Table S2.** Variable definitions.

**Table S3.** Hemoglobin distribution (mean and SD) in each cohort, overall and within strata of sex and eGFR categories.

**Table S4.** Cohort-specific levels of iron saturation (mean and SD).

**Table S5.** Cohort-specific and pooled estimates for the interaction between eGFR and sex. Estimates represent the change in the slope of the relationship between eGFR and hemoglobin.

**Table S6.** Cohort-specific and pooled estimates for the mean difference in hemoglobin in women compared to men at different levels of eGFR.

**Table S7.** Cohort-specific and pooled estimates for the mean difference in hemoglobin per 10 ml/min per 1.73m² increase in eGFR.

**Table S8.** Cohort-specific and pooled estimates for the mean difference in hemoglobin according to etiology of CKD.

**Table S9.** Cohort-specific and pooled estimates for the independent association between covariates and hemoglobin from the extended multivariable model.

**Table S10.** R-squared values for linear regression models applied in participating cohorts.

**Table S11.** Cohort-specific and pooled estimates for the independent association between smoking status and hemoglobin.

**Table S12.** Cohort-specific and pooled estimates for the independent association between altitude and hemoglobin.

**Table S13.** Cohort-specific and pooled estimates for the independent association between smoking status and hemoglobin.

**Table S14.** Cohort-specific and pooled estimates for the mean difference in hemoglobin in women compared to men at different levels of eGFR in ESA-unexposed subgroup.

**Table S15.** Cohort-specific and pooled estimates for the mean difference in hemoglobin according to etiology of CKD in ESA-unexposed subgroup.

**Table S16.** Cohort-specific and pooled estimates for the independent association between covariates and hemoglobin from the extended multivariable model in ESA-unexposed subgroup.

**Table S17.** Complete case analysis including 10 cohorts who provided individual-level data.

**STROBE Statement.**

**REFERENCES**


